BioCentury
ARTICLE | Strategy

DUX4 partnership

January 10, 2013 8:00 AM UTC

Researchers at the Fred Hutchinson Cancer Research Center have identified a mutation that induces expression of the transcription factor double homeobox 4 and could be targeted in facioscapulohumeral muscular dystrophy.1 Based on this and previous research, the team has partnered with GlaxoSmithKline plc to develop small molecule inhibitors against this target, or its downstream effectors, to treat the disease.

The collaboration is the company's third partnership as part of the Discovery Partnerships with Academia program and the first with a U.S.-based institution...